TANDEM DIABETES CARE INC (TNDM)
Sector: Health Care
Sector: Health Care
TANDEM DIABETES CARE INC - Executive Compensation
President and Chief Executive Officer
Executive Compensation
John Sheridan serves as the President and Chief Executive Officer at Tandem Diabetes Care Inc., a leading medical device company focused on developing innovative insulin delivery systems for people with diabetes. Sheridan joined Tandem Diabetes Care in 2019, bringing with him a wealth of experience in the medical device industry. Prior to his current role, he held various leadership positions at companies such as Dexcom, where he served as the Executive Vice President of Operations and Chief Operating Officer. His extensive background in operations and strategic planning has been instrumental in driving Tandem's growth and success. Under Sheridan's leadership, Tandem Diabetes Care has achieved significant milestones, including the launch of the t:slim X2 insulin pump with Control-IQ technology, a groundbreaking system that integrates with continuous glucose monitoring (CGM) devices to help automate insulin delivery. This innovation has been widely praised for its potential to improve diabetes management and quality of life for users. Sheridan's strategic vision has also guided the company through successful collaborations and partnerships, expanding Tandem's global reach and market presence. His commitment to advancing diabetes care is evident in his focus on developing user-friendly, technologically advanced solutions that meet the evolving needs of the diabetes community. As CEO, John Sheridan plays a pivotal role in shaping the future direction of Tandem Diabetes Care. He oversees the company's overall operations, ensuring that Tandem continues to deliver high-quality products and services. Sheridan's leadership style emphasizes innovation, customer-centricity, and operational excellence. He actively engages with the diabetes community, healthcare professionals, and industry stakeholders to gather insights and feedback, which he uses to inform the company's strategic decisions. His dedication to improving the lives of people with diabetes has solidified Tandem's position as a leader in the insulin delivery market, and under his guidance, the company is well-positioned for continued growth and success.